Detalhe da pesquisa
1.
Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.
Clin Transl Sci
; 12(5): 459-469, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30920122
2.
Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study.
J Clin Pharmacol
; 59(5): 654-667, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30681729
3.
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
Cancer Chemother Pharmacol
; 81(4): 727-737, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29468456
4.
Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.
Cancer Chemother Pharmacol
; 81(1): 195-206, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29188322
5.
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Thyroid
; 27(9): 1118-1127, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28741453
6.
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
Cancer Chemother Pharmacol
; 57(5): 685-92, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16133532
7.
Skin sparing mastectomy with delayed implant reconstruction.
Am Surg
; 76(7): 785-7, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20698397
8.
A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.
Cancer Chemother Pharmacol
; 76(4): 777-84, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26281907
9.
Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.
Clin Lung Cancer
; 16(6): 514-22, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26003007
10.
Pharmacokinetics of Nisoldipine Coat--Core Formulation in Subjects with Liver Cirrhosis.
Am J Ther
; 2(1): 15-19, 1995 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11850642
11.
Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.
J Clin Pharmacol
; 52(8): 1240-7, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21868716
12.
Optimizing wound healing in the face after laser abrasion.
J Am Acad Dermatol
; 46(3): 399-407, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11862176